Immutep TACTI-003 Phase IIb Trial Eftilagimod Alpha HNSCC 2024

Phase IIb trial results presenting eftilagimod alpha (soluble LAG-3 fusion protein) combined with pembrolizumab versus pembrolizumab alone for first-line recurrent or metastatic head and neck squamous cell carcinoma. Study evaluated the efficacy of an MHC Class II agonist with anti-PD-1 immunotherapy in patients with CPS ≥1.